Login Register Cart 0
Generic placeholder image

Current Radiopharmaceuticals

Editor-in-Chief

ISSN (Print): 1874-4710
ISSN (Online): 1874-4729

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Methodological Aspects and the Prognostic Value of Metabolic Tumor Volume assessed with 18F-FDG PET/CT in Lymphomas

Author(s): Francesca Tutino*, Elisabetta Giovannini, Sara Pastorino, Ornella Ferrando, Giampiero Giovacchini and Andrea Ciarmiello

Volume 15, Issue 4, 2022

Published on: 25 May, 2022

Page: [259 - 270] Pages: 12

DOI: 10.2174/1874471015666220329120631

Price: $65

Abstract

Although metabolic tumor volume (MTV) assessed with pretreatment 18F-FDG PET/CT has shown significant prognostic value across many lymphoma types, it is still not used in clinical practice due to technical concerns and the lack of standardisation. Numerous studies on the prognostic value of MTV in lymphomas have been published in recent years, but there is still no full agreement on the best methodology for MTV calculation. In this paper, we reviewed the methodological aspects of MTV assessment and reported recent works about its impact on outcome in lymphomas, with a focus on Hodgkin lymphoma (HL) and diffuse large B cell lymphoma (DLBCL).

Keywords: MTV, 18F-FDG PET/TC, lymphomas, survival, automated segmentation, Hodgkin lymphoma.

« Previous Next »
Graphical Abstract

[1]
Specht, L.; Nordentoft, A.M.; Cold, S.; Clausen, N.T.; Nissen, N.I. Tumor burden as the most important prognostic factor in early stage Hodgkin’s disease. Relations to other prognostic factors and implications for choice of treatment. Cancer, 1988, 61(8), 1719-1727.
[http://dx.doi.org/10.1002/1097-0142(19880415)61:8<1719:AIDCNCR2820610834>3.0.CO;2-A] [PMID: 3349432]
[2]
Gobbi, P.G.; Ghirardelli, M.L.; Solcia, M.; Di Giulio, G.; Merli, F.; Tavecchia, L.; Bertè, R.; Davini, O.; Levis, A.; Broglia, C.; Maffè, G.C.; Ilariucci, F.; Dore, R.; Ascari, E. Image-aided estimate of tumor burden in Hodgkin’s disease: Evidence of its primary prognostic importance. J. Clin. Oncol., 2001, 19(5), 1388-1394.
[http://dx.doi.org/10.1200/JCO.2001.19.5.1388] [PMID: 11230483]
[3]
Ceriani, L.; Martelli, M.; Zinzani, P.L.; Ferreri, A.J.; Botto, B.; Stelitano, C.; Gotti, M.; Cabras, M.G.; Rigacci, L.; Gargantini, L.; Merli, F.; Pinotti, G.; Mannina, D.; Luminari, S.; Stathis, A.; Russo, E.; Cavalli, F.; Giovanella, L.; Johnson, P.W.; Zucca, E. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood, 2015, 126(8), 950-956.
[http://dx.doi.org/10.1182/blood-2014-12-616474] [PMID: 26089397]
[4]
Ceriani, L.; Milan, L.; Martelli, M.; Ferreri, A.J.M.; Cascione, L.; Zinzani, P.L.; Di Rocco, A.; Conconi, A.; Stathis, A.; Cavalli, F.; Bellei, M.; Cozens, K.; Porro, E.; Giovanella, L.; Johnson, P.W.; Zucca, E. Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. Blood, 2018, 132(2), 179-186.
[http://dx.doi.org/10.1182/blood-2018-01-826958] [PMID: 29720487]
[5]
Carlier, T.; Bailly, C. State-of-the-art and recent advances in quantification for therapeutic follow-up in oncology using PET. Front. Med. (Lausanne), 2015, 2, 18.
[http://dx.doi.org/10.3389/fmed.2015.00018] [PMID: 26090365]
[6]
Boellaard, R.; Delgado-Bolton, R.; Oyen, W.J.; Giammarile, F.; Tatsch, K.; Eschner, W.; Verzijlbergen, F.J.; Barrington, S.F.; Pike, L.C.; Weber, W.A.; Stroobants, S.; Delbeke, D.; Donohoe, K.J.; Holbrook, S.; Graham, M.M.; Testanera, G.; Hoekstra, O.S.; Zijlstra, J.; Visser, E.; Hoekstra, C.J.; Pruim, J.; Willemsen, A.; Arends, B.; Kotzerke, J.; Bockisch, A.; Beyer, T.; Chiti, A.; Krause, B.J. European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0. Eur. J. Nucl. Med. Mol. Imaging, 2015, 42(2), 328-354.
[http://dx.doi.org/10.1007/s00259-014-2961-x] [PMID: 25452219]
[7]
Burggraaff, C.N.; Rahman, F.; Kaßner, I.; Pieplenbosch, S.; Barrington, S.F.; Jauw, Y.W.S.; Zwezerijnen, G.J.C.; Müller, S.; Hoekstra, O.S.; Zijlstra, J.M.; de Vet, H.C.W.; Boellaard, R. PETRA Consortium. Optimizing workflows for fast and reliable metabolic tumor volume measurements in diffuse large B cell lymphoma. Mol. Imaging Biol., 2020, 22(4), 1102-1110.
[http://dx.doi.org/10.1007/s11307-020-01474-z] [PMID: 31993925]
[8]
Cottereau, A.S.; Hapdey, S.; Chartier, L.; Modzelewski, R.; Casasnovas, O.; Itti, E.; Tilly, H.; Vera, P.; Meignan, M.A.; Becker, S. Baseline total metabolic tumor volume measured with fixed or different adaptive thresholding methods equally predicts outcome in peripheral T cell lymphoma. J. Nucl. Med., 2017, 58(2), 276-281.
[http://dx.doi.org/10.2967/jnumed.116.180406] [PMID: 27754905]
[9]
Barrington, S.F.; Meignan, M. Time to prepare for risk adaptation in lymphoma by standardizing measurement of metabolic tumor burden. J. Nucl. Med., 2019, 60(8), 1096-1102.
[http://dx.doi.org/10.2967/jnumed.119.227249] [PMID: 30954945]
[10]
Kanoun, S.; Tal, I.; Berriolo-Riedinger, A.; Rossi, C.; Riedinger, J.M.; Vrigneaud, J.M.; Legrand, L.; Humbert, O.; Casasnovas, O.; Brunotte, F.; Cochet, A. Influence of software tool and methodological aspects of total metabolic tumor volume calculation on baseline [18F]FDG PET to predict survival in hodgkin lymphoma. PLoS One, 2015, 10(10), e0140830.
[http://dx.doi.org/10.1371/journal.pone.0140830] [PMID: 26473950]
[11]
Tutino, F.; Puccini, G.; Linguanti, F.; Puccini, B.; Rigacci, L.; Kovalchuk, S.; Sciagrà, R.; Berti, V. Baseline metabolic tumor volume calculation using different SUV thresholding methods in Hodgkin lymphoma patients: Interobserver agreement and reproducibility across software platforms. Nucl. Med. Commun., 2021, 42(3), 284-291.
[http://dx.doi.org/10.1097/MNM.0000000000001324] [PMID: 33306623]
[12]
Barrington, S.F.; Zwezerijnen, B.G.J.C.; de Vet, H.C.W.; Heymans, M.W.; Mikhaeel, N.G.; Burggraaff, C.N.; Eertink, J.J.; Pike, L.C.; Hoekstra, O.S.; Zijlstra, J.M.; Boellaard, R. Automated segmentation of baseline metabolic total tumor burden in diffuse large B-cell lymphoma: Which method is most successful? a study on behalf of the PETRA consortium. J. Nucl. Med., 2021, 62(3), 332-337.
[http://dx.doi.org/10.2967/jnumed.119.238923] [PMID: 32680929]
[13]
Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; Tinevez, J.Y.; White, D.J.; Hartenstein, V.; Eliceiri, K.; Tomancak, P.; Cardona, A. Fiji: An open-source platform for biological- image analysis. Nat. Methods, 2012, 9(7), 676-682.
[http://dx.doi.org/10.1038/nmeth.2019] [PMID: 22743772]
[14]
Nioche, C.; Orlhac, F.; Boughdad, S.; Reuzé, S.; Goya-Outi, J.; Robert, C.; Pellot-Barakat, C.; Soussan, M.; Frouin, F.; Buvat, I. LIFEx: A freeware for radiomic feature calculation in multimodality imaging to accelerate advances in the characterization of tumor heterogeneity. Cancer Res., 2018, 78(16), 4786-4789.
[http://dx.doi.org/10.1158/0008-5472.CAN-18-0125] [PMID: 29959149]
[15]
Boellaard, R. Quantitative oncology molecular analysis suite. Accurate. J. Nucl. Med., 2018, 59, 1.
[16]
Engert, A.; Plütschow, A.; Eich, H.T.; Lohri, A.; Dörken, B.; Borchmann, P.; Berger, B.; Greil, R.; Willborn, K.C.; Wilhelm, M.; Debus, J.; Eble, M.J.; Sökler, M.; Ho, A.; Rank, A.; Ganser, A.; Trümper, L.; Bokemeyer, C.; Kirchner, H.; Schubert, J.; Král, Z.; Fuchs, M.; Müller-Hermelink, H.K.; Müller, R.P.; Diehl, V. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N. Engl. J. Med., 2010, 363(7), 640-652.
[http://dx.doi.org/10.1056/NEJMoa1000067] [PMID: 20818855]
[17]
Viviani, S.; Zinzani, P.L.; Rambaldi, A.; Brusamolino, E.; Levis, A.; Bonfante, V.; Vitolo, U.; Pulsoni, A.; Liberati, A.M.; Specchia, G.; Valagussa, P.; Rossi, A.; Zaja, F.; Pogliani, E.M.; Pregno, P.; Gotti, M.; Gallamini, A.; Rota Scalabrini, D.; Bonadonna, G.; Gianni, A.M. Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. ABVD versus BEACOPP for Hodgkin’s lymphoma when high-dose salvage is planned. N. Engl. J. Med., 2011, 365(3), 203-212.
[http://dx.doi.org/10.1056/NEJMoa1100340] [PMID: 21774708]
[18]
Rossi, C.; Casasnovas, O. PET-guided treatment in advanced-stage Hodgkin lymphoma: Yes but which one? Oncotarget, 2019, 10(43), 4354-4355.
[http://dx.doi.org/10.18632/oncotarget.27045] [PMID: 31320989]
[19]
Moghbel, M.C.; Kostakoglu, L.; Zukotynski, K.; Chen, D.L.; Nadel, H.; Niederkohr, R.; Mittra, E. Response assessment criteria and their applications in lymphoma: Part 1. J. Nucl. Med., 2016, 57(6), 928-935.
[http://dx.doi.org/10.2967/jnumed.115.166280] [PMID: 27127227]
[20]
Moghbel, M.C.; Mittra, E.; Gallamini, A.; Niederkohr, R.; Chen, D.L.; Zukotynski, K.; Nadel, H.; Kostakoglu, L. Response assessment criteria and their applications in lymphoma: Part 2. J. Nucl. Med., 2017, 58(1), 13-22.
[http://dx.doi.org/10.2967/jnumed.116.184242] [PMID: 27879369]
[21]
Georgi, T.W.; Kurch, L.; Hasenclever, D.; Warbey, V.S.; Pike, L.; Radford, J.; Sabri, O.; Kluge, R.; Barrington, S.F. Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial. PLoS One, 2020, 15(4), e0231027.
[http://dx.doi.org/10.1371/journal.pone.0231027] [PMID: 32240248]
[22]
D’Urso, D.; Stefano, A.; Romano, A.; Russo, G.; Cosentino, S.; Fallanca, F.; Gioe, M.; Attanasio, M.; Sabini, M.G.; Di Raimondo, F.; Ippolito, M. Analysis of metabolic parameters coming from basal and interim PET in Hodgkin Lymphoma. Current Medical Imaging, 2018, 14, 11.
[23]
Eich, H.T.; Diehl, V.; Görgen, H.; Pabst, T.; Markova, J.; Debus, J.; Ho, A.; Dörken, B.; Rank, A.; Grosu, A.L.; Wiegel, T.; Karstens, J.H.; Greil, R.; Willich, N.; Schmidberger, H.; Döhner, H.; Borchmann, P.; Müller-Hermelink, H.K.; Müller, R.P.; Engert, A. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: Final analysis of the German Hodgkin Study Group HD11 trial. J. Clin. Oncol., 2010, 28(27), 4199-4206.
[http://dx.doi.org/10.1200/JCO.2010.29.8018] [PMID: 20713848]
[24]
André, M.P.E.; Girinsky, T.; Federico, M.; Reman, O.; Fortpied, C.; Gotti, M.; Casasnovas, O.; Brice, P.; van der Maazen, R.; Re, A.; Edeline, V.; Fermé, C.; van Imhoff, G.; Merli, F.; Bouabdallah, R.; Sebban, C.; Specht, L.; Stamatoullas, A.; Delarue, R.; Fiaccadori, V.; Bellei, M.; Raveloarivahy, T.; Versari, A.; Hutchings, M.; Meignan, M.; Raemaekers, J. Early positron emission tomography response-adapted treatment in stage I and II Hodgkin Lymphoma: Final results of the randomized ORTC/LYSA/FIL H10 trial. J. Clin. Oncol., 2017, 35(16), 1786-1794.
[http://dx.doi.org/10.1200/JCO.2016.68.6394] [PMID: 28291393]
[25]
Radford, J.; Illidge, T.; Counsell, N.; Hancock, B.; Pettengell, R.; Johnson, P.; Wimperis, J.; Culligan, D.; Popova, B.; Smith, P.; McMillan, A.; Brownell, A.; Kruger, A.; Lister, A.; Hoskin, P.; O’Doherty, M.; Barrington, S. Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N. Engl. J. Med., 2015, 372(17), 1598-1607.
[http://dx.doi.org/10.1056/NEJMoa1408648] [PMID: 25901426]
[26]
Song, M.K.; Chung, J.S.; Lee, J.J.; Jeong, S.Y.; Lee, S.M.; Hong, J.S.; Chong, A.; Moon, J.H.; Kim, J.H.; Lee, S.M.; Kim, S.J.; Shin, H.J. Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin’s lymphoma. Cancer Sci., 2013, 104(12), 1656-1661.
[http://dx.doi.org/10.1111/cas.12282] [PMID: 24033666]
[27]
Kanoun, S.; Rossi, C.; Berriolo-Riedinger, A.; Dygai-Cochet, I.; Cochet, A.; Humbert, O.; Toubeau, M.; Ferrant, E.; Brunotte, F.; Casasnovas, R.O. Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(9), 1735-1743.
[http://dx.doi.org/10.1007/s00259-014-2783-x] [PMID: 24811577]
[28]
Moskowitz, A.J.; Schöder, H.; Gavane, S.; Thoren, K.L.; Fleisher, M.; Yahalom, J.; McCall, S.J.; Cadzin, B.R.; Fox, S.Y.; Gerecitano, J.; Grewal, R.; Hamlin, P.A.; Horwitz, S.M.; Kumar, A.; Matasar, M.; Ni, A.; Noy, A.; Palomba, M.L.; Perales, M.A.; Portlock, C.S.; Sauter, C.; Straus, D.; Younes, A.; Zelenetz, A.D.; Moskowitz, C.H. Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma. Blood, 2017, 130(20), 2196-2203.
[http://dx.doi.org/10.1182/blood-2017-06-788877] [PMID: 28874350]
[29]
Akhtari, M.; Milgrom, S.A.; Pinnix, C.C.; Reddy, J.P.; Dong, W.; Smith, G.L.; Mawlawi, O.; Abou Yehia, Z.; Gunther, J.; Osborne, E.M.; Andraos, T.Y.; Wogan, C.F.; Rohren, E.; Garg, N.; Chuang, H.; Khoury, J.D.; Oki, Y.; Fanale, M.; Dabaja, B.S. Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. Blood, 2018, 131(1), 84-94.
[http://dx.doi.org/10.1182/blood-2017-04-773838] [PMID: 29038339]
[30]
Cottereau, A.S.; Versari, A.; Loft, A.; Casasnovas, O.; Bellei, M.; Ricci, R.; Bardet, S.; Castagnoli, A.; Brice, P.; Raemaekers, J.; Deau, B.; Fortpied, C.; Raveloarivahy, T.; Van Zele, E.; Chartier, L.; Vander Borght, T.; Federico, M.; Hutchings, M.; Ricardi, U.; Andre, M.; Meignan, M. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood, 2018, 131(13), 1456-1463.
[http://dx.doi.org/10.1182/blood-2017-07-795476] [PMID: 29437590]
[31]
Mettler, J.; Müller, H.; Voltin, C.A.; Baues, C.; Klaeser, B.; Moccia, A.; Borchmann, P.; Engert, A.; Kuhnert, G.; Drzezga, A.E.; Dietlein, M.; Kobe, C. Metabolic tumour volume for response prediction in advanced-stage hodgkin lymphoma. J. Nucl. Med., 2018, jnumed.118.210047.
[PMID: 29880508]
[32]
Lue, K.H.; Wu, Y.F.; Liu, S.H.; Hsieh, T.C.; Chuang, K.S.; Lin, H.H.; Chen, Y.H. Prognostic value of pretreatment radiomic features of 18F-FDG PET in patients with Hodgkin Lymphoma. Clin. Nucl. Med., 2019, 44(10), e559-e565.
[http://dx.doi.org/10.1097/RLU.0000000000002732] [PMID: 31306204]
[33]
Albano, D.; Mazzoletti, A.; Spallino, M.; Muzi, C.; Zilioli, V.R.; Pagani, C.; Tucci, A.; Rossetti, C.; Giubbini, R.; Bertagna, F. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: A two-center experience in 123 patients. Ann. Hematol., 2020, 99(6), 1321-1330.
[http://dx.doi.org/10.1007/s00277-020-04039-w] [PMID: 32333153]
[34]
Milgrom, S.A.; Kim, J.; Chirindel, A.; Kim, J.; Pei, Q.; Chen, L.; Buxton, A.; Kessel, S.; Leal, J.; McCarten, K.M.; Hoppe, B.S.; Wolden, S.L.; Schwartz, C.L.; Friedman, D.L.; Kelly, K.M.; Cho, S.Y. Prognostic value of baseline metabolic tumor volume in children and adolescents with intermediate-risk Hodgkin lymphoma treated with chemo-radiation therapy: FDG-PET parameter analysis in a subgroup from COG AHOD0031. Pediatr. Blood Cancer, 2021, 68(9), e29212.
[http://dx.doi.org/10.1002/pbc.29212] [PMID: 34245210]
[35]
Herraez, I.; Bento, L.; Daumal, J.; Repetto, A.; Del Campo, R.; Perez, S.; Ramos, R.; Ibarra, J.; Mestre, F.; Bargay, J.; Lopez, P.; Garcias-Ladaria, J.; Sampol, A.; Gutierrez, A. Total lesion glycolysis improves tumor burden evaluation and risk assessment at diagnosis in Hodgkin Lymphoma. J. Clin. Med., 2021, 10(19), 10.
[http://dx.doi.org/10.3390/jcm10194396] [PMID: 34640418]
[36]
Zhou, Y.; Zhu, Y.; Chen, Z.; Li, J.; Sang, S.; Deng, S. Radiomic features of 18F-FDG PET in Hodgkin Lymphoma are predictive of outcomes. Contrast Media Mol. Imaging, 2021, 2021, 6347404.
[http://dx.doi.org/10.1155/2021/6347404] [PMID: 34887712]
[37]
Pinochet, P.; Texte, E.; Stamatoullas-Bastard, A.; Vera, P.; Mihailescu, S.D.; Becker, S. Prognostic value of baseline metabolic tumour volume in advanced-stage Hodgkin’s lymphoma. Sci. Rep., 2021, 11(1), 23195.
[http://dx.doi.org/10.1038/s41598-021-02734-w] [PMID: 34853386]
[38]
Frood, R.; Burton, C.; Tsoumpas, C.; Frangi, A.F.; Gleeson, F.; Patel, C.; Scarsbrook, A. Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: A systematic review. Eur. J. Nucl. Med. Mol. Imaging, 2021, 48(10), 3198-3220.
[http://dx.doi.org/10.1007/s00259-021-05233-2] [PMID: 33604689]
[39]
Song, M.K.; Chung, J.S.; Shin, H.J.; Moon, J.H.; Lee, J.O.; Lee, H.S.; Lee, S.M.; Lee, G.W.; Lee, S.E.; Kim, S.J. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci., 2012, 103(3), 477-482.
[http://dx.doi.org/10.1111/j.1349-7006.2011.02164.x] [PMID: 22126515]
[40]
Esfahani, S.A.; Heidari, P.; Halpern, E.F.; Hochberg, E.P.; Palmer, E.L.; Mahmood, U. Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: A pilot study. Am. J. Nucl. Med. Mol. Imaging, 2013, 3(3), 272-281.
[PMID: 23638338]
[41]
Sasanelli, M.; Meignan, M.; Haioun, C.; Berriolo-Riedinger, A.; Casasnovas, R.O.; Biggi, A.; Gallamini, A.; Siegel, B.A.; Cashen, A.F.; Véra, P.; Tilly, H.; Versari, A.; Itti, E. Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma. Eur. J. Nucl. Med. Mol. Imaging, 2014, 41(11), 2017-2022.
[http://dx.doi.org/10.1007/s00259-014-2822-7] [PMID: 24902639]
[42]
Gallicchio, R.; Mansueto, G.; Simeon, V.; Nardelli, A.; Guariglia, R.; Capacchione, D.; Soscia, E.; Pedicini, P.; Gattozzi, D.; Musto, P.; Storto, G. F-18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B-cell lymphoma. Eur. J. Haematol., 2014, 92(5), 382-389.
[http://dx.doi.org/10.1111/ejh.12268] [PMID: 24428392]
[43]
Kim, J.; Hong, J.; Kim, S.G.; Hwang, K.H.; Kim, M.; Ahn, H.K.; Sym, S.J.; Park, J.; Cho, E.K.; Shin, D.B.; Lee, J.H. Prognostic value of metabolic tumor volume estimated by (18) F-FDG positron emission tomography/computed tomography in patients with diffuse large B-Cell lymphoma of stage ii or iii disease. Nucl. Med. Mol. Imaging, 2014, 48(3), 187-195.
[http://dx.doi.org/10.1007/s13139-014-0280-6] [PMID: 25177375]
[44]
Adams, H.J.; de Klerk, J.M.; Fijnheer, R.; Heggelman, B.G.; Dubois, S.V.; Nievelstein, R.A.; Kwee, T.C. Prognostic superiority of the national comprehensive cancer network international prognostic index over pretreatment whole-body volumetric-metabolic fdgpet/ct metrics in diffuse large b-cell lymphoma. Eur. J. Haematol., 2015, 94(6), 532-539.
[http://dx.doi.org/10.1111/ejh.12467] [PMID: 25311082]
[45]
Mikhaeel, N.G.; Smith, D.; Dunn, J.T.; Phillips, M.; Møller, H.; Fields, P.A.; Wrench, D.; Barrington, S.F. Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL. Eur. J. Nucl. Med. Mol. Imaging, 2016, 43(7), 1209-1219.
[http://dx.doi.org/10.1007/s00259-016-3315-7] [PMID: 26902371]
[46]
Zhou, M.; Chen, Y.; Huang, H.; Zhou, X.; Liu, J.; Huang, G. Prognostic value of total lesion glycolysis of baseline 18Ffluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma. Oncotarget, 2016, 7(50), 83544-83553.
[http://dx.doi.org/10.18632/oncotarget.13180] [PMID: 27835875]
[47]
Song, M.K.; Yang, D.H.; Lee, G.W.; Lim, S.N.; Shin, S.; Pak, K.J.; Kwon, S.Y.; Shim, H.K.; Choi, B.H.; Kim, I.S.; Shin, D.H.; Kim, S.G.; Oh, S.Y. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era. Leuk. Res., 2016, 42, 1-6.
[http://dx.doi.org/10.1016/j.leukres.2016.01.010] [PMID: 26851438]
[48]
Cottereau, A.S.; Lanic, H.; Mareschal, S.; Meignan, M.; Vera, P.; Tilly, H.; Jardin, F.; Becker, S. Molecular profile and FDGPET/CT total metabolic tumor volume improve risk classification at diagnosis for patients with diffuse large B-cell lymphoma. Clin. Cancer Res., 2016, 22(15), 3801-3809.
[http://dx.doi.org/10.1158/1078-0432.CCR-15-2825] [PMID: 26936916]
[49]
Chang, C.C.; Cho, S.F.; Chuang, Y.W.; Lin, C.Y.; Chang, S.M.; Hsu, W.L.; Huang, Y.F. Prognostic significance of total metabolic tumor volume on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with diffuse large B-cell lymphoma receiving rituximab-containing chemotherapy. Oncotarget, 2017, 8(59), 99587-99600.
[http://dx.doi.org/10.18632/oncotarget.20447] [PMID: 29245926]
[50]
Ilyas, H.; Mikhaeel, N.G.; Dunn, J.T.; Rahman, F.; Møller, H.; Smith, D.; Barrington, S.F. Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma. Eur. J. Nucl. Med. Mol. Imaging, 2018, 45(7), 1142-1154.
[http://dx.doi.org/10.1007/s00259-018-3953-z] [PMID: 29460024]
[51]
Toledano, M.N.; Desbordes, P.; Banjar, A.; Gardin, I.; Vera, P.; Ruminy, P.; Jardin, F.; Tilly, H.; Becker, S. Combination of baseline FDG PET/CT total metabolic tumour volume and gene expression profile have a robust predictive value in patients with diffuse large B-cell lymphoma. Eur. J. Nucl. Med. Mol. Imaging, 2018, 45(5), 680-688.
[http://dx.doi.org/10.1007/s00259-017-3907-x] [PMID: 29344718]
[52]
Cottereau, A.S.; Nioche, C.; Dirand, A.S.; Clerc, J.; Morschhauser, F.; Casasnovas, O.; Meignan, M.; Buvat, I. 18F-FDG PET Dissemination features in diffuse large B-cell lymphoma are predictive of outcome. J. Nucl. Med., 2020, 61(1), 40-45.
[http://dx.doi.org/10.2967/jnumed.119.229450] [PMID: 31201248]
[53]
Ceriani, L.; Gritti, G.; Cascione, L.; Pirosa, M.C.; Polino, A.; Ruberto, T.; Stathis, A.; Bruno, A.; Moccia, A.A.; Giovanella, L.; Hayoz, S.; Schär, S.; Dirnhofer, S.; Rambaldi, A.; Martinelli, G.; Mamot, C.; Zucca, E. SAKK38/07 study: Integration of baselinemetabolic heterogeneity and metabolic tumor volume in DLBCL prognostic model. Blood Adv., 2020, 4(6), 1082-1092.
[http://dx.doi.org/10.1182/bloodadvances.2019001201] [PMID: 32196557]
[54]
Aide, N.; Fruchart, C.; Nganoa, C.; Gac, A.C.; Lasnon, C. Baseline 18F-FDG PET radiomic features as predictors of 2-year event-free survival in diffuse large B cell lymphomas treated with immunochemotherapy. Eur. Radiol., 2020, 30(8), 4623-4632.
[http://dx.doi.org/10.1007/s00330-020-06815-8] [PMID: 32248365]
[55]
Zhao, P.; Yu, T.; Pan, Z. Prognostic value of the baseline 18F-FDG PET/CT metabolic tumour volume (MTV) and further stratification in low-intermediate (L-I) and high-intermediate (H-I) risk NCCNIPI subgroup by MTV in DLBCL MTV predict prognosis in DLBCL. Ann. Nucl. Med., 2021, 35(1), 24-30.
[http://dx.doi.org/10.1007/s12149-020-01531-1] [PMID: 33001389]
[56]
Zhou, Z.; Sehn, L.H.; Rademaker, A.W.; Gordon, L.I.; Lacasce, A.S.; Crosby-Thompson, A.; Vanderplas, A.; Zelenetz, A.D.; Abel, G.A.; Rodriguez, M.A.; Nademanee, A.; Kaminski, M.S.; Czuczman, M.S.; Millenson, M.; Niland, J.; Gascoyne, R.D.; Connors, J.M.; Friedberg, J.W.; Winter, J.N. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood, 2014, 123(6), 837-842.
[http://dx.doi.org/10.1182/blood-2013-09-524108] [PMID: 24264230]
[57]
Rosenwald, A.; Wright, G.; Chan, W.C.; Connors, J.M.; Campo, E.; Fisher, R.I.; Gascoyne, R.D.; Muller-Hermelink, H.K.; Smeland, E.B.; Giltnane, J.M.; Hurt, E.M.; Zhao, H.; Averett, L.; Yang, L.; Wilson, W.H.; Jaffe, E.S.; Simon, R.; Klausner, R.D.; Powell, J.; Duffey, P.L.; Longo, D.L.; Greiner, T.C.; Weisenburger, D.D.; Sanger, W.G.; Dave, B.J.; Lynch, J.C.; Vose, J.; Armitage, J.O.; Montserrat, E.; López-Guillermo, A.; Grogan, T.M.; Miller, T.P.; LeBlanc, M.; Ott, G.; Kvaloy, S.; Delabie, J.; Holte, H.; Krajci, P.; Stokke, T.; Staudt, L.M. Lymphoma/Leukemia Molecular Profiling Project. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med., 2002, 346(25), 1937-1947.
[http://dx.doi.org/10.1056/NEJMoa012914] [PMID: 12075054]
[58]
Horn, H.; Ziepert, M.; Becher, C.; Barth, T.F.; Bernd, H.W.; Feller, A.C.; Klapper, W.; Hummel, M.; Stein, H.; Hansmann, M.L.; Schmelter, C.; Möller, P.; Cogliatti, S.; Pfreundschuh, M.; Schmitz, N.; Trümper, L.; Siebert, R.; Loeffler, M.; Rosenwald, A.; Ott, G. German High-Grade Non-Hodgkin Lymphoma Study Group. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood, 2013, 121(12), 2253-2263.
[http://dx.doi.org/10.1182/blood-2012-06-435842] [PMID: 23335369]
[59]
Cottereau, A.S.; Becker, S.; Broussais, F.; Casasnovas, O.; Kanoun, S.; Roques, M.; Charrier, N.; Bertrand, S.; Delarue, R.; Bonnet, C.; Hustinx, R.; Gaulard, P.; de Leval, L.; Vera, P.; Itti, E.; Mounier, N.; Haioun, C.; Tilly, H.; Meignan, M. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDGPET/CT in patients with peripheral T-cell lymphoma (PTCL). Ann. Oncol., 2016, 27(4), 719-724.
[http://dx.doi.org/10.1093/annonc/mdw011] [PMID: 26787236]
[60]
Meignan, M.; Cottereau, A.S.; Versari, A.; Chartier, L.; Dupuis, J.; Boussetta, S.; Grassi, I.; Casasnovas, R.O.; Haioun, C.; Tilly, H.; Tarantino, V.; Dubreuil, J.; Federico, M.; Salles, G.; Luminari, S.; Trotman, J. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies. J. Clin. Oncol., 2016, 34(30), 3618-3626.
[http://dx.doi.org/10.1200/JCO.2016.66.9440] [PMID: 27551111]
[61]
Song, M.K.; Chung, J.S.; Yhim, H.Y.; Lim, S.N.; Kim, S.J.; Han, Y.H.; Shim, H.K.; Jung, S.H.; Lee, J.J.; Yang, D.H. Tumor necrosis and complete resection has significant impacts on survival in patients with limited-stage upper aerodigestive tract NK/T cell lymphoma. Oncotarget, 2017, 8(45), 79337-79346.
[http://dx.doi.org/10.18632/oncotarget.18107] [PMID: 29108312]
[62]
Pak, K.; Kim, B.S.; Kim, K.; Kim, I.J.; Jun, S.; Jeong, Y.J.; Shim, H.K.; Kim, S.D.; Cho, K.S. Prognostic significance of standardizeduptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: A multicenter, retrospective analysis. Am. J. Otolaryngol., 2018, 39(1), 1-5.
[http://dx.doi.org/10.1016/j.amjoto.2017.10.009] [PMID: 29056243]
[63]
Delfau-Larue, M.H.; van der Gucht, A.; Dupuis, J.; Jais, J.P.; Nel, I.; Beldi-Ferchiou, A.; Hamdane, S.; Benmaad, I.; Laboure, G.; Verret, B.; Haioun, C.; Copie-Bergman, C.; Berriolo-Riedinger, A.; Robert, P.; Casasnovas, R.O.; Itti, E. Total metabolic tumor volume, circulating tumor cells, cell-free DNA: Distinct prognostic value in follicular lymphoma. Blood Adv., 2018, 2(7), 807-816.
[http://dx.doi.org/10.1182/bloodadvances.2017015164] [PMID: 29636326]
[64]
Zhou, Y.; Zhang, X.; Qin, H.; Zhao, Z.; Li, J.; Zhang, B.; Sang, S.; Wu, Y.; Deng, S. Prognostic values of baseline 18F-FDG PET/CT in patients with peripheral T-cell lymphoma. BioMed Res. Int., 2020, 2020, 9746716.
[http://dx.doi.org/10.1155/2020/9746716] [PMID: 32185229]
[65]
Cottereau, A.S.; El-Galaly, T.C.; Becker, S.; Broussais, F.; Petersen, L.J.; Bonnet, C.; Prior, J.O.; Tilly, H.; Hutchings, M.; Casasnovas, O.; Meignan, M. Predictive value of PET response combined with baseline metabolic tumor volume in peripheral Tcell lymphoma patients. J. Nucl. Med., 2018, 59(4), 589-595.
[http://dx.doi.org/10.2967/jnumed.117.193946] [PMID: 28864629]
[66]
Versari, A.; Iotti, C.; Merli, F. Impact of PET on the radiation treatment of Hodgkins Lymphoma. Curr. Radiopharm., 2009, 2, 6.
[http://dx.doi.org/10.2174/1874471010902030169]
[67]
Tout, M.; Casasnovas, O.; Meignan, M.; Lamy, T.; Morschhauser, F.; Salles, G.; Gyan, E.; Haioun, C.; Mercier, M.; Feugier, P.; Boussetta, S.; Paintaud, G.; Ternant, D.; Cartron, G. Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: A Lymphoma Study Association report. Blood, 2017, 129(19), 2616-2623.
[http://dx.doi.org/10.1182/blood-2016-10-744292] [PMID: 28251914]
[68]
Repetto-Llamazares, A.H.; Larsen, R.H.; Mollatt, C.; Lassmann, M.; Dahle, J. Biodistribution and dosimetry of (177)Lu-tetulomab, a new radioimmunoconjugate for treatment of non-Hodgkin lymphoma. Curr. Radiopharm., 2013, 6(1), 20-27.
[http://dx.doi.org/10.2174/1874471011306010004] [PMID: 23256748]
[69]
Massicano, A.V.; Pujatti, P.B.; Alcarde, L.F.; Suzuki, M.F.; Spencer, P.J.; Araujo, E.B. Development and biological studies of (1)(7)(7)Lu-DOTA-rituximab for the treatment of Non-Hodgkin’s lymphoma. Curr. Radiopharm., 2016, 9, 54-63.
[http://dx.doi.org/10.2174/1874471008666150313103849] [PMID: 25771373]
[70]
Kong, F.L.; Ford, R.J.; Yang, D.J. Managing lymphoma with non- FDG radiotracers: Current clinical and preclinical applications. BioMed Res. Int., 2013, 2013, 626910.
[http://dx.doi.org/10.1155/2013/626910 ] [PMID: 23841079]

Rights & Permissions Print Cite
Article Metrics
36
2
© 2024 Bentham Science Publishers | Privacy Policy